Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Chemotherapy, Hormone, Biologic therapy.

King's College Hospital, London, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:3City/State/Province:London
Treatments:Chemotherapy, Hormone, Biologic therapyHospital:King's College Hospital
Drugs:Journal:Link
Date:Dec 2011

Description:

Patients:
This phase II study involved 15 adult T-cell leukemia lymphoma (ATLL) patients with a median age of 48 years; 2 were male.

Treatment:
Patients were treated with a combination of the biologic therapy agent Zenapax (also known as daclizumab; a monoclonal antibody against CD25 that directs the immune system to attack cancer cells), the chemotherapy agents cyclophosphamide, doxorubicin, vincristine, and the hormone prednisolone.

Toxicities:
The maximum toxicity grade was 3, including neurotoxicity, infection, and gastrointestinal toxicity.

Results:
The median overall survival was 10 months.

Support:
This study was partially supported by Roche Pharmaceuticals, makers of Zenepax.

Correspondence: Dr. Antonio Pagliuca; email: [email protected]



Back